인공지능 플랫폼 고도화를 위한 양질의 데이터 생산기지 역할, 디어젠만의 인공지능 융합 신약개발플랫폼(DEARGEN iDears) 완성
Read More
Deargen begins full operation of iDear Center for AI-convergence drug development
Deargen has completed the end-to-end AI drug development platform ‘DEARGEN iDeas” to serve as a high-quality data productino for advancing its platform.
Read More
[Interview] “Deargen enhances its pipeline to accelerate the AI-powered new drug development.”
Inhwan Bae, CDO of Deargen, said through the iDear Center that Deargen will enhance the preclinical pipeline and be in full swing of innovative drug development.
Read More
[인터뷰] “디어젠, 파이프라인 강화로 AI 신약개발 가속화”
배인환 CDO 인터뷰, iDear Center를 통한 전임상 파이프라인 강화, 혁신 신약 개발 본격화
Read More
[인터뷰] “AI 신약 개발사, 기술력과 중·장기적 비즈니스 모델 갖춰야”
배영철 CBO 인터뷰, 아미노산 서열 분석으로 혁신신약 후보물질 발굴, 각 제약사에 맞는 플랫폼 판매도 계획
Read More
“AI drug discovery companies should have technical skills and mid-to-long-term business model.”
One of the most significant business models for AI drug development companies is collaborating with global companies..
Read More
Deargen-NeogenTC, Announced a research collaboration on developing an AI platform for cancer immunotherapy.
Deargen starts a research collaboration with NeogenTC to develop a TCR-T treatment prediction platform using Deargen’s sequence-based AI technology.
Read More
디어젠-네오젠TC, AI면역세포 치료제 플랫폼 공동연구
디어젠이 네오젠TC와 함께 시퀀스기반 AI기술을 활용한 TCR-T치료제 예측플랫폼 개발을 시작했습니다.
Read More
[Interview] “Dongtan RnD Center, iDear Center, will be an outpost of anti-cancer drugs”
The first interview article on Kilsoo Kang, CEO of Deargen, after he successfully secured the SeriesB funding round.
Read More
“동탄연구소 아이디어센터, 항암신약 개발 전초기지로”
강길수 디어젠 대표이사, 시리즈B 완료 이후 첫 인터뷰 기사 공개
Read More